North America Microelectrode Array In Vitro Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis
No. of Pages: 101 | Report Code: BMIRE00032080 | Category: Life Sciences
No. of Pages: 101 | Report Code: BMIRE00032080 | Category: Life Sciences
The North America microelectrode array in vitro market was valued at US$ 8.44 million in 2023 and is expected to reach US$ 11.94 million by 2031; it is estimated to register a CAGR of 4.4% from 2023 to 2031.
Neuroscience research involves testing new drugs on neuronal cultures to evaluate their effects on neural activity and develop targeted treatments. Researchers utilize in vitro models to investigate a variety of neurological and neuropsychiatric diseases, including Alzheimer's disease, Parkinson's disease, and epilepsy, as well as various neurodevelopmental disorders. The increasing prevalence of such neurological disorders increases the demand for microelectrode array systems in neuroscience research. Microelectrode arrays in vitro allow for the examination of specific cellular and molecular changes related to neurological conditions, and their effects on neural functions. By measuring neural activity in in vitro cell models using microelectrode arrays, researchers can assess drug compounds' ability to modulate neural activity, restore normal network function, or counteract disease-related abnormalities. This information is essential for identifying promising drug candidates at an early stage during development. With the growing utilization of microelectrode arrays in neuroscience research laboratories, market players such as Axion BioSystems, Multi Channel Systems, and MaxWell Biosystems are adopting strategies to launch innovative products in the market. For instance, in April 2024, Axion BioSystems launched the Maestro Volt, an affordable benchtop microelectrode array system tailored for academic labs with lower throughput needs. This 6-well device, suitable for neurological and cardiovascular research, offers user-friendly features and high-quality controls associated with the company’s Maestro brand. Therefore, a surge in neuroscience research for developing new drugs for neurodegenerative diseases boosts the demand for microelectrode arrays in vitro, which drives the market.
Investors are increasingly focusing on companies that produce high-throughput microelectrode arrays for in vitro research, a critical requirement for research institutions, pharmaceutical industries, and the biotechnological sector. Innovations in CMOS-based microelectrode arrays, stem cell research, neuroprosthetics, and in vitro toxicology testing are driving the demand for microelectrode arrays. In June 2020, Georgia State University Research Foundation, Inc. was granted US$ 197.56 million by the US National Science Foundation for their project, which involved the development of microelectrode array sensors for SARS-CoV-2 and other RNA viruses. The project offered a unique opportunity for measurement science to tackle a societal and global crisis through innovative research. In 2011, the US Environmental Protection Agency highlighted that microelectrode arrays are a valuable system for conducting in vitro toxicity tests, including assessments of developmental neurotoxicity, which presents a significant challenge in the development and approval of new chemicals and drugs. These supportive guidelines by the regulatory bodies in the US have led to the increasing utilization of microelectrode arrays for high-throughput screening in drug discovery and disease modeling as researchers seek reliable platforms for real-time monitoring of cellular and tissue activity. The growing adoption of microelectrode arrays in vitro models such as organoids has led to the development of innovative technologies, including 3D microelectrode array technology and CMOS-based high-density microelectrode array technology. For instance, in January 2023, BMSEED, a US-based provider of microelectrode array technologies, filed a non-provisional patent application for the advancement of its 2D stretchable microelectrode array (sMEA) into the third dimension, creating the 3D-sMEA. This technology allows electrophysiological measurements from brain organoids and 3D tissue cultures, particularly focused on Alzheimer's disease. The 3D-sMEA features adjustable pockets with embedded electrodes that conform to organoids, enabling researchers to record neural signals from ~80% of the surface area of intact organoids. Thus, the higher rate of early adoption of emerging microelectrode array technologies and the rising research in the fields of neuroscience, cardiology, and toxicology for creating new therapies for neurological and cardiovascular diseases are likely to increase the demand for microelectrode array in vitro solutions across the US in the near future.
The North America microelectrode array in vitro market is categorized into product, application, and country.
Based on product, the North America microelectrode array in vitro market is divided into classical MEA, multiwell-MEA, and CMOS-MEA. The multiwell-MEA segment held the largest North America microelectrode array in vitro market share in 2023.
In terms of application, the North America microelectrode array in vitro market is segmented into cardiomyocytes, nerve, and others. The cardiomyocytes segment held the largest North America microelectrode array in vitro market share in 2023.
By country, the North America microelectrode array in vitro market is segmented into the US, Canada, and Mexico. The US dominated the North America microelectrode array in vitro market share in 2023.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 8.44 Million |
| Market Size by 2031 | US$ 11.94 Million |
| CAGR (2023 - 2031) | 4.4% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
|
Tucker Davis Technologies; SCREEN Holdings Co., Ltd.; Plexon Inc.; MaxWell Biosystems AG; Harvard Bioscience Inc.; Axion BioSystems Inc; 3Brain AG; NeuroNexus Technologies Inc.; MicroElectrodeDevices; Blackrock Microsystems, Inc.; NMI Technologietransfer GmbH; and BMSEED are some of the leading companies operating in the microelectrode array in vitro market.
The North America Microelectrode Array In Vitro Market is valued at US$ 8.44 Million in 2023, it is projected to reach US$ 11.94 Million by 2031.
As per our report North America Microelectrode Array In Vitro Market, the market size is valued at US$ 8.44 Million in 2023, projecting it to reach US$ 11.94 Million by 2031. This translates to a CAGR of approximately 4.4% during the forecast period.
The North America Microelectrode Array In Vitro Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Microelectrode Array In Vitro Market report:
The North America Microelectrode Array In Vitro Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Microelectrode Array In Vitro Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Microelectrode Array In Vitro Market value chain can benefit from the information contained in a comprehensive market report.
E 1803, Panchshil Towers, Vagholi, Haveli, Pune- 412207, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Microelectrode Array In Vitro Market
